Indaptus Therapeutics, Inc.
INDPHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, Indaptus Therapeutics, Inc. (INDP) is listed under Biotechnology. At a $337.1M market cap, Indaptus Therapeutics, Inc. ranks as a small-cap company within healthcare. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
Market Cap
$337.1M
Beta
1.14
P/E (TTM)
—
P/E (Fwd)
-1.82
EPS (TTM)
$-12.65
EPS (Fwd)
$-1.39
ROE
-931.8%
ROA
-286.8%
Cash
$1.5M
Total Debt
$0
Free CF
-$10.8M
52W Change
-78.2%
Annual Financials
Cash vs Debt
Indaptus Therapeutics, Inc. reports $1.5M in cash and $0 in total debt. Free cash flow is running at -$10.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -931.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Indaptus Therapeutics, Inc. and its sector.